{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:51:35Z","timestamp":1784886695044,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:00:00Z","timestamp":1593302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100017655","name":"Friedberg Charitable Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017655","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018864","name":"Making Headway Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018864","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NYU CTSA","award":["TL1 TR001447"],"award-info":[{"award-number":["TL1 TR001447"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pleomorphic xanthoastrocytoma (PXA) is a rare type of brain tumor that affects children and young adults. Molecular prognostic markers of PXAs remain poorly established. Similar to gangliogliomas, PXAs show prominent immune cell infiltrate, but its composition also remains unknown. In this study, we correlated DNA methylation and BRAF status with clinical outcome and explored the tumor microenvironment. We performed DNA methylation in 21 tumor samples from 18 subjects with a histological diagnosis of PXA. MethylCIBERSORT was used to deconvolute the PXA microenvironment by analyzing the associated immune cell-types. Median age at diagnosis was 16\u2009years (range 7\u201332). At median follow-up of 30\u2009months, 3-year and 5-year overall survival was 73% and 71%, respectively. Overall survival ranged from 1 to 139\u2009months. Eleven out of 18 subjects (61%) showed disease progression. Progression-free survival ranged from 1 to 89\u2009months. Trisomy 7 and CDKN2A\/B (p16) homozygous deletion did not show any association with overall survival (p\u2009=\u20090.67 and p\u2009=\u20090.74, respectively). Decreased overall survival was observed for subjects with tumors lacking the BRAF V600E mutation (p\u2009=\u20090.02). PXAs had significantly increased CD8 T-cell epigenetic signatures compared with previously profiled gangliogliomas (p\u2009=\u20090.0019). The characterization of immune cell-types in PXAs may have implications for future development of immunotherapy.<\/jats:p>","DOI":"10.1093\/jnen\/nlaa051","type":"journal-article","created":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T22:23:57Z","timestamp":1593383037000},"page":"880-890","source":"Crossref","is-referenced-by-count":13,"title":["Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma"],"prefix":"10.1093","volume":"79","author":[{"given":"Karen","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology From the , New York University Langone Health, New York, New York"},{"name":"Clinical and Translational Science Institute , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kurland","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varshini","family":"Vasudevaraja","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Delorenzo","sequence":"additional","affiliation":[{"name":"Department of Neuropathology , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Radmanesh","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheddhi","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Neuropathology , New York University Langone Health, New York, New York"},{"name":"Department of Neuropathology, Incyte Diagnostics , Spokane Valley, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Spino","sequence":"additional","affiliation":[{"name":"Department of Neuropathology , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Gardner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology From the , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology From the , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Nicolaides","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology From the , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana S","family":"Osorio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology , Oncology and\u00a0Bone Marrow Transplant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L","family":"Finlay","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology , Oncology and\u00a0Bone Marrow Transplant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Bou\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine , Nationwide Children\u2019s Hospital, and the Ohio State University, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Snuderl","sequence":"additional","affiliation":[{"name":"Department of Neuropathology , New York University Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,28]]},"reference":[{"key":"2024032523332403400_nlaa051-B1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11060-012-0939-8","article-title":"Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: A SEER analysis","volume":"110","author":"Perkins","year":"2012","journal-title":"J Neurooncol"},{"key":"2024032523332403400_nlaa051-B2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.12669\/pjms.342.14663","article-title":"Pleomorphic xanthoastrocytoma; clinicopathological spectrum of an intriguing neoplasm","volume":"34","author":"Abid","year":"2018","journal-title":"Pak J Med Sci"},{"key":"2024032523332403400_nlaa051-B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"70","author":"Kulis","year":"2010","journal-title":"Adv Genet"},{"key":"2024032523332403400_nlaa051-B4","first-page":"143","article-title":"The role of DNA methylation in cancer development","volume":"44","author":"Luczak","year":"2006","journal-title":"Folia Histochem Cytobiol"},{"key":"2024032523332403400_nlaa051-B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"2024032523332403400_nlaa051-B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2407-14-213","article-title":"DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma","volume":"14","author":"Mart\u00ednez","year":"2014","journal-title":"BMC Cancer"},{"key":"2024032523332403400_nlaa051-B7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/cas.13903","article-title":"Genome-wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma","volume":"110","author":"Nakamura","year":"2019","journal-title":"Cancer Sci"},{"key":"2024032523332403400_nlaa051-B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bpa.12217","article-title":"Pleomorphic xanthoastrocytoma: Natural history and long-term follow-up","volume":"25","author":"Ida","year":"2015","journal-title":"Brain Pathol"},{"key":"2024032523332403400_nlaa051-B9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bpa.12495","article-title":"Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation","volume":"28","author":"Vaubel","year":"2018","journal-title":"Brain Pathol"},{"key":"2024032523332403400_nlaa051-B10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/sj.onc.1209851","article-title":"Frequent loss of chromosome 9, homozygous CDKN2A\/p14(ARF)\/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas","volume":"26","author":"Weber","year":"2007","journal-title":"Oncogene"},{"key":"2024032523332403400_nlaa051-B11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","article-title":"BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma","volume":"33","author":"Mistry","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024032523332403400_nlaa051-B12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/bpa.12566","article-title":"Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis","volume":"28","author":"Korshunov","year":"2018","journal-title":"Brain Pathol"},{"key":"2024032523332403400_nlaa051-B13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-015-1405-4","article-title":"Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers","volume":"129","author":"Korshunov","year":"2015","journal-title":"Acta Neuropathol"},{"key":"2024032523332403400_nlaa051-B14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol"},{"key":"2024032523332403400_nlaa051-B15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-7659-1_2","article-title":"Whole genome DNA methylation analysis of human glioblastoma using illumina BeadArrays","volume":"1741","author":"Serrano","year":"2018","journal-title":"Methods Mol Biol"},{"key":"2024032523332403400_nlaa051-B16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell"},{"key":"2024032523332403400_nlaa051-B17","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/neuonc\/nou138","article-title":"Assessing CpG island methylator phenotype, 1p\/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial","volume":"16","author":"Wiestler","year":"2014","journal-title":"Neuro Oncol"},{"key":"2024032523332403400_nlaa051-B18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00401-014-1315-x","article-title":"Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma","volume":"128","author":"Wiestler","year":"2014","journal-title":"Acta Neuropathol"},{"key":"2024032523332403400_nlaa051-B19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40478-016-0361-0","article-title":"Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation","volume":"4","author":"Orillac","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"2024032523332403400_nlaa051-B20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-016-1639-9","article-title":"Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): An epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway","volume":"133","author":"Huse","year":"2017","journal-title":"Acta Neuropathol"},{"key":"2024032523332403400_nlaa051-B21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-017-2431-y","article-title":"Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: A genome-wide analysis","volume":"133","author":"Richardson","year":"2017","journal-title":"J Neurooncol"},{"key":"2024032523332403400_nlaa051-B22","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1038\/s41467-018-05570-1","article-title":"Pan-cancer deconvolution of tumour composition using DNA methylation","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun"},{"key":"2024032523332403400_nlaa051-B23","first-page":"265","article-title":"Clinico-histomorphological and immunohistochemical profile of anaplastic pleomorphic xanthoastrocytoma: Report of five cases and review of literature","volume":"12","author":"Pradhan","year":"2018","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"2024032523332403400_nlaa051-B24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bpa.12639","article-title":"The genetic landscape of anaplastic pleomorphic xanthoastrocytoma","volume":"29","author":"Phillips","year":"2019","journal-title":"Brain Pathol"},{"key":"2024032523332403400_nlaa051-B25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.humpath.2018.08.038","article-title":"Molecular features of pleomorphic xanthoastrocytoma","volume":"86","author":"Zou","year":"2019","journal-title":"Hum Pathol"},{"key":"2024032523332403400_nlaa051-B26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bpa.12295","article-title":"Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas\u2014Same entity or first cousins?","volume":"26","author":"Alexandrescu","year":"2016","journal-title":"Brain Pathol"},{"key":"2024032523332403400_nlaa051-B27","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ejso.2015.09.012","article-title":"BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma","volume":"41","author":"Tabouret","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"2024032523332403400_nlaa051-B28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.it.2019.05.009","article-title":"Towards immunotherapy for pediatric brain tumors","volume":"40","author":"Wang","year":"2019","journal-title":"Trends Immunol"},{"key":"2024032523332403400_nlaa051-B29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PPO.0b013e3182431a73","article-title":"Immunotherapy for the treatment of glioblastoma","volume":"18","author":"Thomas","year":"2012","journal-title":"Cancer J"}],"container-title":["Journal of Neuropathology &amp; Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/79\/8\/880\/40419873\/jnen_79_8_880.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/79\/8\/880\/40419873\/jnen_79_8_880.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T23:49:10Z","timestamp":1711410550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnen\/article\/79\/8\/880\/5864503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,28]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,6,28]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnen\/nlaa051","relation":{},"ISSN":["0022-3069","1554-6578"],"issn-type":[{"value":"0022-3069","type":"print"},{"value":"1554-6578","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,6,28]]}}}